Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: Topical Unani Formulation: Form: Habb(Pill) to be used in the form of Tila(liniment), Route of Administration: Topical Application, Quantity: Quantity sufficient based on the extent of
Sponsors
National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Participants of any gender in age group of 18-60 years 2. Participants of Quba (Tinea Corporis and Tinea Cruris) having circumscribed lesions with any of the following signs and symptoms on body, limbs and groin: a. Presence of pruritus and burning b. Presence of scales c. Presence of central clearing d. Erythematous papules 3. Participants with Positive KOH (10%) Smear Microscopy of Skin Scrapping from the active lesion for Dermatophytic Hyphae
Exclusion criteria
Exclusion criteria: 1. Age below 18 years and above 60 years 2. Patients with other form of tinea infection like tinea capitis (head), tinea pedis (foot), tinea mannum (hands), tinea unguium (nails), tinea barbae (beard), tinea faciei (face), etc. 3. Patients with other concomitant diseases like psoriasis & eczema 4. Patients who have received any topical antifungal therapy within last 2 weeks or oral antifungal therapy in the previous 4 weeks 5. Participants not willing to give consent and to attend treatment schedule regularly 6. Patients with known active pulmonary/cardiovascular/ liver/ renal or neurological diseases 7. Known cases of Diabetes Mellitus or other immunocompromised disorders (HIV/ AIDS, etc.)/ Malignancies 8. Patients with long-term history of steroid, cytotoxic and immunosuppressive therapy 9. History of hypersensitivity to either Terbinafine or any test drug 10. Pregnant or lactating women, and women desiring pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in Total Signs & Symptoms Score (TSSS). 2. Change in mycology finding (KOH mount).Timepoint: TSSS at baseline, 2nd, 4th and 6th week KOH mount at baseline and 42nd day | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.DLQI (Dermatology Life Quality Index) 2.Systemic Safety AssessmentTimepoint: DLQI at baseline, 2nd, 4th and 6th week Systemic Safety Assessment at baseline and 6th week | — |
Countries
India
Contacts
Public ContactDr Farhana Farheen Aqueel Ahmed
National Research Institute of Unani Medicine for Skin Disorders, Hyderabad
Outcome results
None listed